Back to Search Start Over

Recipient Outcomes With Extended Criteria Donors Using Advanced Heart Preservation: An Analysis of the GUARDIAN-Heart Registry.

Authors :
Moayedifar, Roxana
Shudo, Yasuhiro
Kawabori, Masashi
Silvestry, Scott
Schroder, Jacob
Meyer, Dan M.
Jacobs, Jeffrey P.
D'Alessandro, David
Zuckermann, Andreas
Source :
Journal of Heart & Lung Transplantation. Apr2024, Vol. 43 Issue 4, p673-680. 8p.
Publication Year :
2024

Abstract

The prevalence of end-stage heart failure and patients who could benefit from heart transplantation requires an expansion of the donor pool, relying on the transplant community to continually re-evaluate and expand the use of extended criteria donor organs. Introduction of new technologies such as the Paragonix SherpaPak Cardiac Transport System aids in this shift. We seek to analyze the impact of the SherpaPak system on recipient outcomes who receive extended criteria organs in the GUARDIAN-Heart Registry. Between October 2015 and December 2022, 1,113 adults from 15 US centers receiving donor hearts utilizing either SherpaPak (n = 560) or conventional ice storage (ice, n = 453) were analyzed from the GUARDIAN-Heart Registry using summary statistics. A previously published set of criteria was used to identify extended criteria donors, which included 193 SherpaPak and 137 ice. There were a few baseline differences among recipients in the 2 cohorts; most notably, IMPACT scores, distance traveled, and total ischemic time were significantly greater in SherpaPak, and significantly more donor hearts in the SherpaPak cohort had >4 hours total ischemia time. Posttransplant mechanical circulatory support utilization (SherpaPak 22.3% vs ice 35.0%, p = 0.012) and new extracorporeal membrane oxygenation/ventricular assist device (SherpaPak 7.8% vs ice 15.3%, p = 0.033) was significantly reduced, and the rate of severe primary graft dysfunction (SherpaPak 6.2% vs ice 13.9%, p = 0.022) was significantly reduced by over 50% in hearts preserved using SherpaPak. One-year survival between cohorts was similar (SherpaPak 92.9% vs ice 89.6%, p = 0.27). This subgroup analysis demonstrates that SherpaPak can be safely used to utilize extended criteria donors with low severe PGD rates. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
10532498
Volume :
43
Issue :
4
Database :
Academic Search Index
Journal :
Journal of Heart & Lung Transplantation
Publication Type :
Academic Journal
Accession number :
176034437
Full Text :
https://doi.org/10.1016/j.healun.2023.12.013